Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection - BJT-778-001

Next Previous
Trial Profile

A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection - BJT-778-001

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brelovitug (Primary) ; Sodium chloride
  • Indications Hepatitis B; Hepatitis D
  • Focus Adverse reactions
  • Sponsors Bluejay Therapeutics; Mirum Pharmaceuticals

Most Recent Events

  • 26 Jan 2026 According to Mirum Pharmaceuticals media release, Bluejay Therapeutics has been acquired and merged into Mirum Pharmaceuticals.
  • 07 Oct 2025 According to Bluejay Therapeutics media release, data from the trial will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, taking place November 7-11, 2025 in Washington, D.C.
  • 04 Sep 2025 Planned End Date changed to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top